[ad_1]
The shares of CELLECT BIOTECH / S (NASDAQ: APOP) received an average broker rating of 1.00 (Strong Purchase) of According to a stock research badyst, the 39; equity research badyst felt that the action was highly recommended.
Brokers set a year – long consensual goal of $ 14.00 for the company and expect that the Zacks company also awarded to CELLECT BIOTECH / S a ranking of 112 out of 255 according to the ratings given to related companies.
A number of badysts Zacks Investment Research has upgraded the shares of CELLECT BIOTECH / S from a "hold" rating to a "buy" rating and set a target price of 7.25 $ for the company in a research report on Friday, April 6th. a "buy" a note sd will set a target price of $ 14.00 on the shares of CELLECT BIOTECH / S in a research note on Tuesday, May 29. Finally, ValuEngine has updated the shares of CELLECT BIOTECH / S from a "sale" rating to a "sustain" rating in a research note on Wednesday, June 6th.
A hedge fund recently acquired a new equity stake in CELLECT BIOTECH / SA. Sabby Management LLC bought a new equity position in CELLECT BIOTECH / S (NASDAQ: APOP) during the first quarter, according to the company in its most recent filing 13F with the SEC. The institutional investor bought 243,980 shares of the company, valued at approximately $ 1,557,000. CELLECT BIOTECH / S represents 0.2% of the investment portfolio of Sabby Management LLC, which places the stock at 23rd place. Sabby Management LLC held approximately 4.48% of CELLECT BIOTECH / S at the time of filing with the SEC. Hedge funds and other institutional investors hold 6.22% of the company's shares.
APOP shares fell $ 0.38 during the day on Thursday, reaching $ 6.70. The company had a trading volume of 17,100 shares, compared to its average volume of 57,938. CELLECT BIOTECH / S had a year-low of $ 6.12 and a high of 13.50 $ in one year. The company has a market capitalization of $ 38.95 million, a price / earnings ratio of -4.79 and a beta of 4.68.
CELLECT BIOTECH / S (NASDAQ: APOP) last published its financial results on Thursday, May 17th. The company reported ($ 0.16) earnings per share (EPS) for the quarter, leading consensus badyst estimates of ($ 0.30) by $ 0.14. Analysts expect CELLECT BIOTECH / S to display -1 EPS for the current fiscal year.
About CELLECT BIOTECH / S
Cellect Biotechnology Ltd., a biotechnology company, focuses on the development of technologies for the functional selection of stem cells in the field of regenerative medicine and cell therapies in Israel. Develops the Apotainer Selection Kit, a stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures in patients with hematological malignancies
Momentum Indicator: Relative Strength Index
Get a Free Copy of Zacks' Research Report on CELLECT BIOTECH / S (APOP)
For more information about the offers of search for Zacks Investment Research, visit Zacks.com
News and Comments for CELLECT BIOTECH / S Daily – Enter your email address below to receive a daily concise summary of the latest news and notes from 39 badysts for CELLECT BIOTECH / S and affiliates with MarketBeat.com's free daily newsletter. 19659011]
[ad_2]
Source link
